US mRNA Therapeutics Market Size to Attain USD 38.21 Bn By 2033

The US mRNA therapeutics market size is expected to increase to USD 38.21 billion by 2033 from USD 11.07 billion in 2023 with a CAGR of 13.21% between 2024 and 2033.

mRNA therapeutics represent a groundbreaking approach to drug development, offering the potential to treat a wide range of diseases by harnessing the body’s own cellular machinery to produce therapeutic proteins. In the United States, the mRNA therapeutics market is experiencing rapid growth, driven by advances in mRNA technology, increasing investment from pharmaceutical companies, and a growing pipeline of mRNA-based therapies targeting various diseases.

mRNA Therapeutics Market Size in the US 2024 to 2033

Key Points

By type, the prophylactic vaccines segment held the largest share of the market in 2023.
By application, the infectious disease segment led the market in 2023. The segment is observed to sustain the growth rate during the forecast period.
By end-use, the hospital and clinics segment held the largest share of the market in 2023. The segment is expected to sustain its position throughout the forecast period.

Growth Factors:

Several factors contribute to the growth of the US mRNA therapeutics market. Firstly, the success of mRNA COVID-19 vaccines has catapulted mRNA technology into the spotlight, highlighting its potential for rapid vaccine development and demonstrating its safety and efficacy. This success has led to increased investment in mRNA research and development from both pharmaceutical companies and government agencies. Additionally, the versatility of mRNA technology allows for the development of therapies for a wide range of diseases, including cancer, infectious diseases, and genetic disorders, further driving market growth.

Get a Sample: https://www.precedenceresearch.com/sample/3862

Trends:

In the US mRNA therapeutics market, several trends are shaping the industry landscape. One significant trend is the expansion of mRNA-based vaccine development beyond infectious diseases to include cancer immunotherapy and personalized medicine. Another trend is the development of novel mRNA delivery systems and formulations to enhance stability, efficacy, and target specificity of mRNA therapeutics. Additionally, the increasing collaboration between pharmaceutical companies and biotech startups is accelerating the pace of innovation in mRNA technology and driving the development of new therapeutic applications.

US mRNA Therapeutics Market Scope

Report Coverage	Details
Growth Rate from 2024 to 2033	CAGR of 13.21%
U.S. Market Size in 2023	USD 11.07 Billion
U.S. Market Size by 2033	USD 38.21 Billion
Base Year	2023
Forecast Period	2024 to 2033
Segments Covered	By Type, By Application, and By End User

SWOT Analysis

A SWOT analysis of the US mRNA therapeutics market reveals its internal strengths and weaknesses, as well as external opportunities and threats. Strengths include the proven success of mRNA vaccines, growing investment in mRNA research and development, and a robust pipeline of mRNA-based therapies. Weaknesses may include challenges related to manufacturing scalability, delivery system optimization, and potential immune responses to mRNA therapeutics. Opportunities lie in the expansion of mRNA technology into new therapeutic areas, partnerships with academic institutions and research organizations, and regulatory support for expedited approval pathways. Threats may include competition from alternative therapeutic modalities, intellectual property disputes, and regulatory uncertainties.

Recent Developments:

In July 2023, MIT scientists are leading a three-year research study financed by the U.S. Food and Drug Administration (FDA) Center for Biologics Evaluation and Research that intends to build the first fully integrated, continuous mRNA production platform in history. The project is valued at $82 million. In addition to accelerating the development and production of mRNA technologies—which businesses are investing in at previously unheard-of levels in the hopes of creating novel vaccines and treatments for cancer, metabolic disorders, genetic diseases, and other conditions—the resulting pilot-scale system is meant to strengthen society’s capacity to respond to pandemics in the future.

Competitive Landscape:

The US mRNA therapeutics market is characterized by intense competition among key players such as Moderna Inc., Pfizer Inc. (in collaboration with BioNTech SE), CureVac NV, Translate Bio Inc., and Arcturus Therapeutics Holdings Inc. These companies compete based on factors such as technological innovation, clinical development pipelines, manufacturing capabilities, and strategic partnerships. Additionally, intellectual property rights and regulatory approvals play a significant role in shaping the competitive landscape of the market. Overall, the US mRNA therapeutics market is poised for significant growth and innovation, driven by the transformative potential of mRNA technology in revolutionizing the treatment of various diseases.